2022年华东医药股份有限公司一季报

The First Quarterly Report 2022 of Huadong Medicine Co., Ltd. Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2022-022 Huadong Medicine Co., Ltd. The First Quarterly Report 2022 The Company and all members of the Board of Directors hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions. Important Declaration: 1.The Board of Directors, Board of Supervisors, directors, supervisors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities. 2.The Company’s legal representative and the officer in charge of accounting, and head of accounting department (accounting supervisor) hereby declare and guarantee that the financial statements in this quarter report are authentic, accurate and complete. 3.Has the first quarterly report been audited? □ Yes √ No This report is prepared both in Chinese and English. Should there be any discrepancy between the Chinese and English versions, the Chinese version shall prevail. I. Key financial data (I) Key Accounting Data and Financial Indicators Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data □ Yes √ No Change of the current The current reporting period Same period last year reporting period over the same period last year Operating revenue (yuan) 8,932,579,251.75 8,896,632,277.36 0.40% The First Quarterly Report 2022 of Huadong Medicine Co., Ltd. Net profit attributable to shareholders of 704,364,775.13 758,380,756.56 -7.12% listed companies (yuan) Net profit attributable to shareholders of listed companies after deducting 698,524,004.62 695,792,411.78 0.39% non-recurring gains/losses (yuan) Net cash flow from operating activities (yuan) -260,603,628.32 302,314,164.48 -186.20% Basic earnings per share (yuan/share) 0.4025 0.4334 -7.13% Diluted earnings per share (yuan/share) 0.4025 0.4334 -7.13% Weighted average return on equity (ROE) 4.17% 5.04% -0.87% Change of the end of the End of the current reporting End of last year current reporting period period over the end of last year Total assets (yuan) 28,436,893,634.69 26,996,403,366.69 5.34% Net assets attributable to shareholders of 17,268,724,312.96 16,579,374,323.08 4.16% listed companies (yuan) (II)Items and amounts of non-recurring gains/losses √Applicable □ N/A Amount of the current Item Note reporting period Gains/losses on disposal of non-current assets (including the 1,085,520.17 written-off part of the accrued assets impairment reserve) Government grants included in current gains/losses(excluding those closely related to normal operating activities, in line with 10,669,007.70 national policies and measured according to unified national standards) Other non-operating income or expenditure -5,011,007.02 Less: Amount affected by income tax 997,808.09 Amount affected by minority interest (after tax) -95,057.75 Total 5,840,770.51 -- Details of other gains/losses items satisfying the definition of non-recurring gains/losses: □Applicable √ N/A No such case. If the Company recognizes a non-recurring gain/loss listed in the “InterpretativeAnnouncement No. 1 on Information Disclosure Criteria for Public Companies – Non-Recurring Profit/Loss” as a recurring gain/loss, reasons should be specified. □Applicable √ N/A No such case. The First Quarterly Report 2022 of Huadong Medicine Co., Ltd. (III)Changes in key accounting data and financial indicators and their reasons √Applicable □ N/A Balance sheet item End of the period Beginning of the Change Notes on cause of changes period rate Prepayments 358,007,960.17 275,353,134.69 30.02%Mainly due to the increase in repayments for goods Other receivables 361,937,153.49 223,707,267.30 61.79%Mainly due to the increase of payment of land auction money and security deposit in the current period Short-term borrowings 749,826,858.51 1,237,843,228.13 -39.42%Mainly due to loan repayment in the current period Notes payable 1,241,696,835.09 671,964,504.00 84.79%Mainly due to the increase of bill payment in the current period Dividends payable 224,219.60 2,184,219.60 -89.73%Mainly due to payment of dividends to minority shareholders in the current period Long term loan 478,247,000.00 139,178,905.04 243.62%Mainly due to newly increased borrowings in the current period Other current liabilities 15,546,972.37 11,386,267.11 36.54%Mainly due to the transfer of increased corresponding tax items in contract liabilities into other current liabilities Income statement item Amount of the Amount of the Change Notes on cause of changes current period previous period rate R&D expenses 319,207,245.09 220,005,691.36 45.09%Mainly due to the increase in R&D expenses Other income 10,669,007.70 76,459,624.41 -86.05%Mainly due to the year-on-year decrease in government subsidies obtained in the current period Non-operating expenses 5,355,930.46 3,024,042.00 77.11%Mainly due to the year-on-year increase in external donations in the current period Minority interest income 9,667,799.11 16,093,227.89 -39.93%Mainly due to that Hudong Ningbo is no longer included in the consolidated statements in the current period Cash flow statement item Amount of the Amount of the Change Notes on cause of changes current period previous period rate Net cash flows from operating -260,603,628.32 302,314,164.48 -186.20%Mainly due to the year-on-year decrease in activities sales receipts and government subsidies, the payment of security deposit, and the increase in R&D expenses Net cash flows from financing -5,561,294.58 113,196,714.88 -104.91%Mainly due to the year-on-year decrease in activities borrowing obtained in the current period The First Quarterly Report 2022 of Huadong Medicine Co., Ltd. II. Shareholder information (I) Total number of shareholders of common shares and number of shareholders of preferred shares with voting rights restored, as well as information about top 10 shareholders Unit: share Total number of shareholders Total number of shareholders of of preferred shares whose common shares at the end of the